{"type":"trials","record":{"id":41438,"source_id":"clinicaltrials-gov","external_id":"NCT06795048","title":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","brief_summary":"This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.","overall_status":"Active Not Recruiting","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Hoffmann-La Roche","enrollment":274,"countries":["United States","Australia","Canada","China","France","Germany","Italy","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"start_date":"2025-03-14","completion_date":"2027-09-20","last_update_date":"2026-07-31","source_url":"https://clinicaltrials.gov/study/NCT06795048","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"CONSTANCE","age_range":"50 Years","comparator":null,"organization":"Hoffmann-La Roche","interventions":["Faricimab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52 — Baseline and ave…","Change from Baseline in BCVA Score Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100","Change from Baseline in BCVA Score Over Time — From Baseline to Week 100","Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time — From Baseline to Week 100","Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time — From Baseline to Week 100","Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time — From Baseline to Week 100","Change from Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44, 48, and 52 — Baseline and average of W…","Change from Baseline in CST Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100","Change from Baseline in CST Over Time — From Baseline to Week 100","Percentage of Participants on Different Treatment Intervals at Weeks 52 and 100 — Weeks 52 and 100","Incidence and Severity of Ocular Adverse Events — From first study treatment to Week 100","Incidence and Severity of Non-Ocular Adverse Events — From first study treatment to Week 100"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD)","Faricimab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06795048","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-03-14 to 2027-09-20","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.813Z","intervention":["Faricimab"],"participants":274,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52 — Baseline and ave…","Change from Baseline in BCVA Score Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100","Change from Baseline in BCVA Score Over Time — From Baseline to Week 100","Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time — From Baseline to Week 100","Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time — From Baseline to Week 100","Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time — From Baseline to Week 100","Change from Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44, 48, and 52 — Baseline and average of W…","Change from Baseline in CST Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100","Change from Baseline in CST Over Time — From Baseline to Week 100","Percentage of Participants on Different Treatment Intervals at Weeks 52 and 100 — Weeks 52 and 100","Incidence and Severity of Ocular Adverse Events — From first study treatment to Week 100","Incidence and Severity of Non-Ocular Adverse Events — From first study treatment to Week 100"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41438","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}